Lonza | LONN - Operating Profit


Lonza reported CHF673M in Operating Profit for its fiscal semester ending in June of 2025.





Operating Profit Change Date
Akzo Nobel EUR 254M 37M Mar/2026
Alcon AG USD 297M 16M Mar/2026
Almirall EUR 30.23M 12.8M Dec/2025
AstraZeneca USD 7.11B 4.14B Mar/2026
BASF EUR 1.4B 1.58B Mar/2026
Bayer EUR 3.53B 2.42B Mar/2026
Beiersdorf EUR 504M 312M Dec/2025
Covestro EUR -324M 5.72B Dec/2025
Demant DKK 2.09B 224M Dec/2025
Fresenius EUR 713M 139M Dec/2025
Fresenius Medical Care EUR 268M 395M Mar/2026
Geberit CHF 134.1M 65.8M Dec/2025
Genmab DKK 260M 199M Dec/2025
Givaudan CHF 610M 149M Dec/2025
GlaxoSmithKline GBP 2.29B 856M Mar/2026
GN Store Nord DKK -68M 638M Mar/2026
Hikma Pharmaceutical USD 348M 161M Dec/2025
Johnson Matthey GBP 198M 56M Jun/2026
Merck EUR 1.05B 572M Mar/2026
Novartis USD 4.24B 171M Mar/2026
Philips EUR 302M 417M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.94B 239M Mar/2026
Sika AG CHF 724.9M 73.2M Dec/2025
Smith & Nephew USD 440M 50M Dec/2025
Solvay EUR 118M 58M Mar/2026
UCB EUR 1.29B 571M Dec/2025